These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28932894)

  • 21. FDG PET imaging in patients with pathologically verified dementia.
    Hoffman JM; Welsh-Bohmer KA; Hanson M; Crain B; Hulette C; Earl N; Coleman RE
    J Nucl Med; 2000 Nov; 41(11):1920-8. PubMed ID: 11079505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Case Report of Early-Onset Alzheimer's Disease Using
    Yoo J; Cheon M; Kang MJ
    Diagnostics (Basel); 2023 May; 13(10):. PubMed ID: 37238154
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Rowe CC; Doré V; Jones G; Baxendale D; Mulligan RS; Bullich S; Stephens AW; De Santi S; Masters CL; Dinkelborg L; Villemagne VL
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2053-2059. PubMed ID: 28643043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of (18)FDG PET and (11)C-PIB PET brain imaging on the diagnosis of Alzheimer's disease and other dementias in a regional memory clinic in Hong Kong.
    Shea YF; Ha J; Lee SC; Chu LW
    Hong Kong Med J; 2016 Aug; 22(4):327-33. PubMed ID: 27313272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 11C-DTBZ and 18F-FDG PET measures in differentiating dementias.
    Koeppe RA; Gilman S; Joshi A; Liu S; Little R; Junck L; Heumann M; Frey KA; Albin RL
    J Nucl Med; 2005 Jun; 46(6):936-44. PubMed ID: 15937303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extremely Low Prevalence of Amyloid Positron Emission Tomography Positivity in Parkinson's Disease without Dementia.
    Mashima K; Ito D; Kameyama M; Osada T; Tabuchi H; Nihei Y; Yoshizaki T; Noguchi E; Tanikawa M; Iizuka T; Date Y; Ogata Y; Nakahara T; Iwabuchi Y; Jinzaki M; Murakami K; Suzuki N
    Eur Neurol; 2017; 77(5-6):231-237. PubMed ID: 28285306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.
    Barthel H; Gertz HJ; Dresel S; Peters O; Bartenstein P; Buerger K; Hiemeyer F; Wittemer-Rump SM; Seibyl J; Reininger C; Sabri O;
    Lancet Neurol; 2011 May; 10(5):424-35. PubMed ID: 21481640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting.
    Perani D; Cerami C; Caminiti SP; Santangelo R; Coppi E; Ferrari L; Pinto P; Passerini G; Falini A; Iannaccone S; Cappa SF; Comi G; Gianolli L; Magnani G
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):499-508. PubMed ID: 26341365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia.
    Nestor PJ; Altomare D; Festari C; Drzezga A; Rivolta J; Walker Z; Bouwman F; Orini S; Law I; Agosta F; Arbizu J; Boccardi M; Nobili F; Frisoni GB;
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1509-1525. PubMed ID: 29736698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined evaluation of FDG-PET and MRI improves detection and differentiation of dementia.
    Dukart J; Mueller K; Horstmann A; Barthel H; Möller HE; Villringer A; Sabri O; Schroeter ML
    PLoS One; 2011 Mar; 6(3):e18111. PubMed ID: 21448435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimization of image reconstruction conditions with phantoms for brain FDG and amyloid PET imaging.
    Akamatsu G; Ikari Y; Nishio T; Nishida H; Ohnishi A; Aita K; Sasaki M; Sasaki M; Senda M
    Ann Nucl Med; 2016 Jan; 30(1):18-28. PubMed ID: 26337533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia.
    Cerami C; Della Rosa PA; Magnani G; Santangelo R; Marcone A; Cappa SF; Perani D
    Neuroimage Clin; 2015; 7():187-94. PubMed ID: 25610780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Feasibility and acceptance of simultaneous amyloid PET/MRI.
    Schütz L; Lobsien D; Fritzsch D; Tiepolt S; Werner P; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Rullmann M; Sattler B; Patt M; Gertz HJ; Villringer A; Claßen J; Hoffmann KT; Sabri O; Barthel H
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2236-2243. PubMed ID: 27435367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic Accuracy of MRI and Additional [18F]FDG-PET for Behavioral Variant Frontotemporal Dementia in Patients with Late Onset Behavioral Changes.
    Vijverberg EG; Wattjes MP; Dols A; Krudop WA; Möller C; Peters A; Kerssens CJ; Gossink F; Prins ND; Stek ML; Scheltens P; van Berckel BN; Barkhof F; Pijnenburg YA
    J Alzheimers Dis; 2016 Jun; 53(4):1287-97. PubMed ID: 27372646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Role of Single-Subject Brain Metabolic Patterns in the Early Differential Diagnosis of Primary Progressive Aphasias and in Prediction of Progression to Dementia.
    Cerami C; Dodich A; Greco L; Iannaccone S; Magnani G; Marcone A; Pelagallo E; Santangelo R; Cappa SF; Perani D
    J Alzheimers Dis; 2017; 55(1):183-197. PubMed ID: 27662315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the Amyloid Load in the Brains of Two Transgenic Alzheimer's Disease Mouse Models Quantified by Florbetaben Positron Emission Tomography.
    Willuweit A; Schöneck M; Schemmert S; Lohmann P; Bremen S; Honold D; Burda N; Jiang N; Beer S; Ermert J; Willbold D; Shah NJ; Langen KJ
    Front Neurosci; 2021; 15():699926. PubMed ID: 34671235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Added value and limitations of amyloid-PET imaging: review and analysis of selected cases of mild cognitive impairment and dementia.
    Weidman DA; Zamrini E; Sabbagh MN; Jacobson S; Burke A; Belden C; Powell J; Bhalla N; Roontiva A; Kuang X; Luo J; Chen K; Riggs G; Burke W
    Neurocase; 2017 Feb; 23(1):41-51. PubMed ID: 28376695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-Alzheimer types of neurodegenerative dementia: clinical and 18F-FDG-PET/CT pictures.
    Grassetto G; Marzola MC; Musto A; Viniamury S; Colletti PM; Perkins AC; Rubello D
    Nucl Med Commun; 2014 Nov; 35(11):1085-92. PubMed ID: 25162962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B.
    Meyer PT; Hellwig S; Amtage F; Rottenburger C; Sahm U; Reuland P; Weber WA; Hüll M
    J Nucl Med; 2011 Mar; 52(3):393-400. PubMed ID: 21321269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic value of FDG-PET and HMPAO-SPET in patients with mild dementia and mild cognitive impairment: metabolic index and perfusion index.
    Döbert N; Pantel J; Frölich L; Hamscho N; Menzel C; Grünwald F
    Dement Geriatr Cogn Disord; 2005; 20(2-3):63-70. PubMed ID: 15908747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.